USE OF PHOSPHOLIPIDS IN THE TREATMENT OF DEGENERATIVE LUNG DISEASE SUCH AS COPD OR CYSTIC FIBROSIS AND TO ENHANCE DELIVERY OF DRUGS
摘要
Surface active phospholipid (SAPL) is administered as a dry powder for the treatment of neutrophil-induced or irreversible degenerative lung disease, especially chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF). The SAPL powder is also used in combination therapy to enhance the delivery of biologically active substances to airways to treat COPD and CF, and to enhance the delivery of other actives via mucosal membranes.
申请公布号
WO02094283(A3)
申请公布日期
2003.11.27
申请号
WO2002GB02196
申请日期
2002.05.21
申请人
BRITANNIA PHARMACEUTICALS LIMITED;HILLS, BRIAN, ANDREW;WOODCOCK, DEREK;STANIFORTH, JOHN;CONWAY, JOY;THOMPSON, JIM
发明人
HILLS, BRIAN, ANDREW;WOODCOCK, DEREK;STANIFORTH, JOHN;CONWAY, JOY;THOMPSON, JIM